Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment

References

• Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004;447(5):619–628. doi:10.1007/s00424-003-1067-2
   PubMed Web of Science ®Google Scholar
• Bisbach CM, Hass DT, Thomas ED, Cherry TJ, Hurley JB. Monocarboxylate Transporter 1 (MCT1) mediates succinate export in the retina. Invest Ophthalmol Vis Sci. 2022;63(4):1. doi:10.1167/iovs.63.4.1
   PubMed Web of Science ®Google Scholar
• Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol. 1993;264(4 Pt 1):C761–782. doi:10.1152/ajpcell.1993.264.4.C761
   PubMed Web of Science ®Google Scholar
• Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res Dordr. 2001;18(12):1669–1676. doi:10.1023/A:1013310210710
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Poole RC, Cranmer SL. Mechanisms and regulation of lactate, pyruvate and ketone body transport across the plasma membrane of mammalian cells and their metabolic consequences. Biochem Soc Trans. 1990;18(6):1132–1135. doi:10.1042/bst0181132
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. 1999;343(Pt 2):281–299. doi:10.1042/bj3430281
   PubMed Web of Science ®Google Scholar
• Wang N, Jiang X, Zhang S, et al. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. Cell. 2021;184(2):370–383 e313. doi:10.1016/j.cell.2020.11.043
   PubMed Web of Science ®Google Scholar
• Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion. 2014;17:76–100. doi:10.1016/j.mito.2014.05.007
   PubMed Web of Science ®Google Scholar
• Halestrap AP. The SLC16 gene family - structure, role and regulation in health and disease. Mol Aspects Med. 2013;34(2–3):337–349. doi:10.1016/j.mam.2012.05.003
   PubMed Web of Science ®Google Scholar
• Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000;350(Pt 1):219–227. doi:10.1042/bj3500219
   PubMedGoogle Scholar
• Halestrap AP. The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life. 2012;64(1):1–9. doi:10.1002/iub.573
   PubMed Web of Science ®Google Scholar
• Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000;529(Pt 2):285–293. doi:10.1111/j.1469-7793.2000.00285.x
   PubMed Web of Science ®Google Scholar
• Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. J Mol Med. 2016;94(2):155–171. doi:10.1007/s00109-015-1307-x
   PubMed Web of Science ®Google Scholar
• Philp NJ, Yoon HY, Lombardi L. Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia. Am J Physiol Cell Ph. 2001;280(5):C1319–C1326. doi:10.1152/ajpcell.2001.280.5.C1319
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Doyen J, Trastour C, Ettore F, et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Bioph Res Co. 2014;451(1):54–61. doi:10.1016/j.bbrc.2014.07.050
   PubMed Web of Science ®Google Scholar
• Fei F, Guo X, Chen Y, et al. Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer. J Cancer Res Clin Oncol. 2015;141(6):1095–1102. doi:10.1007/s00432-014-1877-y
   PubMed Web of Science ®Google Scholar
• Payen VL, Mina E, Van Hee VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66. doi:10.1016/j.molmet.2019.07.006
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40. doi:10.1016/j.pharmthera.2008.09.005
   PubMed Web of Science ®Google Scholar
• Wu PH, Zhou Y, Guo YZ, Zhang SL, Tam KY. Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents. Drug Discov Today. 2021;26(3):836–844. doi:10.1016/j.drudis.2021.01.003
   PubMed Web of Science ®Google Scholar
• Galic S, Schneider HP, Broer A, Deitmer JW, Broer S. The loop between helix 4 and helix 5 in the monocarboxylate transporter MCT1 is important for substrate selection and protein stability. Biochem J. 2003;376(2):413–422. doi:10.1042/bj20030799
   PubMedGoogle Scholar
• Futagi Y, Sasaki S, Kobayashi M, Narumi K, Furugen A, Iseki K. The flexible cytoplasmic loop 3 contributes to the substrate affinity of human monocarboxylate transporters. Biochim Biophys Acta Biomembr. 2017;1859(10):1790–1795. doi:10.1016/j.bbamem.2017.05.014
   PubMed Web of Science ®Google Scholar
• Price NT, Jackson VN, Halestrap AP. Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J. 1998;329(Pt 2):321–328. doi:10.1042/bj3290321
   PubMedGoogle Scholar
• Rahman B, Schneider HP, Broer A, Deitmer JW, Broer S. Helix 8 and helix 10 are involved in substrate recognition in the rat monocarboxylate transporter MCT1. Biochemistry. 1999;38(35):11577–11584. doi:10.1021/bi990973f
   PubMed Web of Science ®Google Scholar
• Manoharan C, Wilson MC, Sessions RB, Halestrap AP. The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity. Mol Membr Biol. 2006;23(6):486–498. doi:10.1080/09687860600841967
   PubMed Web of Science ®Google Scholar
• Nancolas B, Sessions RB, Halestrap AP. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity. Biochem J. 2015;467(1):192. doi:10.1042/bj4670192
   PubMedGoogle Scholar
• Sasaki S, Kobayashi M, Futagi Y, Ogura J, Yamaguchi H, Iseki K. Involvement of Histidine Residue His382 in pH regulation of MCT4 activity. PLoS One. 2015;10(4):e0122738. doi:10.1371/journal.pone.0122738
   PubMed Web of Science ®Google Scholar
• Sasaki S, Kobayashi M, Futagi Y, et al. Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4). PLoS One. 2013;8(7):e67690. doi:10.1371/journal.pone.0067690
   PubMed Web of Science ®Google Scholar
• Li XF, Yu XZ, Dai D, Song XY, Xu WG. The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget. 2016;7(17):23141–23155. doi:10.18632/oncotarget.8153
   PubMedGoogle Scholar
• Igakura T, Kadomatsu K, Kaname T, et al. A null mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-implantation development and spermatogenesis. Dev Biol. 1998;194(2):152–165. doi:10.1006/dbio.1997.8819
   PubMed Web of Science ®Google Scholar
• Muramatsu T, Miyauchi T. Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol. 2003;18(3):981–987. doi:10.14670/HH-18.981
   PubMed Web of Science ®Google Scholar
• Hanna SM, Kirk P, Holt OJ, Puklavec MJ, Brown MH, Barclay AN. A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochem. 2003;4(1):17. doi:10.1186/1471-2091-4-17
   PubMedGoogle Scholar
• Ochrietor JD, Moroz TP, van Ekeris L, et al. Retina-specific expression of 5A11/Basigin-2, a member of the immunoglobulin gene superfamily. Invest Ophthalmol Vis Sci. 2003;44(9):4086–4096. doi:10.1167/iovs.02-0995
   PubMed Web of Science ®Google Scholar
• Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19(15):3896–3904. doi:10.1093/emboj/19.15.3896
   PubMed Web of Science ®Google Scholar
• Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011;108(40):16663–16668. doi:10.1073/pnas.1106123108
   PubMed Web of Science ®Google Scholar
• Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem. 2005;280(29):27213–27221. doi:10.1074/jbc.M411950200
   PubMed Web of Science ®Google Scholar
• Wilson MC, Meredith D, Halestrap AP. Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ. J Biol Chem. 2002;277(5):3666–3672. doi:10.1074/jbc.M109658200
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim Y, Lee JH, Kim YS. Prognostic significance of lactate/proton symporters MCT1, MCT4, and Their Chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology. 2014;84(1):245.e9–245.e15. doi:10.1016/j.urology.2014.03.031
   Web of Science ®Google Scholar
• Afonso J, Santos LL, Miranda-Goncalves V, et al. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol Carcinog. 2015;54(11):1451–1466. doi:10.1002/mc.22222
   PubMed Web of Science ®Google Scholar
• Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13(15):4407–4414. doi:10.1158/1078-0432.CCR-07-0109
   PubMed Web of Science ®Google Scholar
• Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol. 2011;28(4):1363–1372. doi:10.1007/s12032-010-9582-4
   PubMed Web of Science ®Google Scholar
• Puri S, Juvale K. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure-activity relationship insights. Eur J Med Chem. 2020;199:112393. doi:10.1016/j.ejmech.2020.112393
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. doi:10.1038/nrc704
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Copetti T, De Saedeleer CJ, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7(3):e33418. doi:10.1371/journal.pone.0033418
   PubMed Web of Science ®Google Scholar
• Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001. doi:10.4161/cc.8.23.10238
   PubMed Web of Science ®Google Scholar
• Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle. 2011;10(11):1772–1783. doi:10.4161/cc.10.11.15659
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930–3942. doi:10.1172/JCI36843
   PubMed Web of Science ®Google Scholar
• Ayala FRR, Rocha RM, Carvalho KC, et al. Glut1 and Glut3 as potential prognostic markers for oral squamous cell carcinoma. Molecules. 2010;15(4):2374–2387. doi:10.3390/molecules15042374
   PubMed Web of Science ®Google Scholar
• Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16(3):919–928. doi:10.1677/ERC-08-0211
   PubMed Web of Science ®Google Scholar
• Wang X, Liu H, Ni Y, Shen P, Han X. Lactate shuttle: from substance exchange to regulatory mechanism. Hum Cell. 2022;35(1):1–14. doi:10.1007/s13577-021-00622-z
   PubMed Web of Science ®Google Scholar
• Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. 2012;18(10):1319–1330. doi:10.2174/138161212799504902
   PubMed Web of Science ®Google Scholar
• Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–3692. doi:10.1172/JCI69741
   PubMed Web of Science ®Google Scholar
• Amrutkar M, Berg K, Balto A, et al. Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis. Cancer Cell Int. 2023;23(1). doi:10.1186/s12935-023-02852-7
   PubMed Web of Science ®Google Scholar
• Meijer TW, Schuurbiers OC, Kaanders JH, et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer. 2012;76(3):316–323. doi:10.1016/j.lungcan.2011.11.006
   PubMed Web of Science ®Google Scholar
• Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011;11(1):167. doi:10.1186/1471-2407-11-167
   PubMedGoogle Scholar
• Hashimoto T, Masuda S, Taguchi S, Brooks GA. Immunohistochemical analysis of MCT1, MCT2 and MCT4 expression in rat plantaris muscle. J Physiol. 2005;567(1):121–129. doi:10.1113/jphysiol.2005.087411
   PubMed Web of Science ®Google Scholar
• Murray CM, Hutchinson R, Bantick JR, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol. 2005;1(7):371–376. doi:10.1038/nchembio744
   PubMed Web of Science ®Google Scholar
• Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery. 2004;55(6):1410–1419. doi:10.1227/01.NEU.0000143034.62913.59
   PubMed Web of Science ®Google Scholar
• De Saedeleer CJ, Porporato PE, Copetti T, et al. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration. Oncogene. 2014;33(31):4060–4068. doi:10.1038/onc.2013.454
   PubMed Web of Science ®Google Scholar
• Dietl K, Renner K, Dettmer K, et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol. 2010;184(3):1200–1209. doi:10.4049/jimmunol.0902584
   PubMed Web of Science ®Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812–3819. doi:10.1182/blood-2006-07-035972
   PubMed Web of Science ®Google Scholar
• Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–161. doi:10.1038/s41577-020-0406-2
   PubMed Web of Science ®Google Scholar
• Yuan C, Zhang J, Lou J, et al. Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis. Bioengineered. 2021;12(1):3850–3863. doi:10.1080/21655979.2021.1951928
   PubMed Web of Science ®Google Scholar
• Long Y, Gao Z, Hu X, et al. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. Cancer Med. 2018;7(9):4690–4700. doi:10.1002/cam4.1713
   PubMed Web of Science ®Google Scholar
• Sun X, Wang M, Wang M, et al. Role of proton-coupled monocarboxylate transporters in cancer: from metabolic crosstalk to therapeutic potential. Front Cell Dev Biol. 2020;8:651. doi:10.3389/fcell.2020.00651
   PubMed Web of Science ®Google Scholar
• Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem. 2005;280(51):41928–41939. doi:10.1074/jbc.M508718200
   PubMed Web of Science ®Google Scholar
• Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111–23115. doi:10.1074/jbc.M202487200
   PubMed Web of Science ®Google Scholar
• Hunt TK, Aslam RS, Beckert S, et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal. 2007;9(8):1115–1124. doi:10.1089/ars.2007.1674
   PubMedGoogle Scholar
• Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72(11):1493–1505. doi:10.1016/j.bcp.2006.04.011
   PubMed Web of Science ®Google Scholar
• Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappa B/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71(7):2550–2560. doi:10.1158/0008-5472.CAN-10-2828
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu MS, Zou C, et al. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-kappaB pathway. Cancer Lett. 2014;342(1):150–158. doi:10.1016/j.canlet.2013.08.042
   PubMed Web of Science ®Google Scholar
• Hong CS, Graham NA, Gu W, et al. MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep. 2016;14(7):1590–1601. doi:10.1016/j.celrep.2016.01.057
   PubMed Web of Science ®Google Scholar
• Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. Bmc Cancer. 2011;11:11. doi:10.1186/1471-2407-11-11
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Calorini L, Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Sign. 2011;14(12):2361–2371. doi:10.1089/ars.2010.3727
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70(17):6945–6956. doi:10.1158/0008-5472.CAN-10-0785
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Marini A, Giannoni E, et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012;72(19):5130–5140. doi:10.1158/0008-5472.CAN-12-1949
   PubMed Web of Science ®Google Scholar
• Shi H, Jiang H, Wang L, et al. Overexpression of monocarboxylate anion transporter 1 and 4 in T24-induced cancer-associated fibroblasts regulates the progression of bladder cancer cells in a 3D microfluidic device. Cell Cycle. 2015;14(19):3058–3065. doi:10.1080/15384101.2015.1053666
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang Y, Dong D, et al. MCT1 regulates aggressive and metabolic phenotypes in bladder cancer. J Cancer. 2018;9(14):2492–2501. doi:10.7150/jca.25257
   PubMed Web of Science ®Google Scholar
• Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007;67(9):4182–4189. doi:10.1158/0008-5472.CAN-06-3184
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–1690. doi:10.3390/cancers6031670
   PubMed Web of Science ®Google Scholar
• Chen P, Zuo H, Xiong H, et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114(3):580–585. doi:10.1073/pnas.1614035114
   PubMed Web of Science ®Google Scholar
• Mu X, Shi W, Xu Y, et al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle. 2018;17(4):428–438. doi:10.1080/15384101.2018.1444305
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Wilson MC. The monocarboxylate transporter family--role and regulation. IUBMB Life. 2012;64(2):109–119. doi:10.1002/iub.572
   PubMed Web of Science ®Google Scholar
• Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705–713. doi:10.1038/nrc2468
   PubMed Web of Science ®Google Scholar
• Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4(6):727–732. doi:10.1242/dmm.007724
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–185. doi:10.1016/j.cmet.2006.02.002
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–197. doi:10.1016/j.cmet.2006.01.012
   PubMed Web of Science ®Google Scholar
• Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1 alpha-dependent mechanism. J Biol Chem. 2006;281(14):9030–9037. doi:10.1074/jbc.M511397200
   PubMed Web of Science ®Google Scholar
• Ke X, Fei F, Chen YK, et al. Hypoxia upregulates CD147 through a combined effect of HIF-1 and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis. 2012;33(8):1598–1607. doi:10.1093/carcin/bgs196
   PubMed Web of Science ®Google Scholar
• Jamali S, Klier M, Ames S, et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep. 2015;5(1):13605. doi:10.1038/srep13605
   PubMedGoogle Scholar
• Nagpal I, Yuan ZM. The basally expressed p53-mediated homeostatic function. Front Cell Dev Biol. 2021;9:775312. doi:10.3389/fcell.2021.775312
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–431. doi:10.1016/j.cell.2009.04.037
   PubMed Web of Science ®Google Scholar
• Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009;9(10):691–700. doi:10.1038/nrc2715
   PubMed Web of Science ®Google Scholar
• Boidot R, Vegran F, Meulle A, et al. Regulation of Monocarboxylate Transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012;72(4):939–948. doi:10.1158/0008-5472.CAN-11-2474
   PubMed Web of Science ®Google Scholar
• Doherty JR, Yang C, Scott KE, et al. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014;74(3):908–920. doi:10.1158/0008-5472.CAN-13-2034
   PubMed Web of Science ®Google Scholar
• Gabay M, Li YL, Felsher DW. MYC Activation is a hallmark of cancer initiation and maintenance. Csh Perspect Med. 2014;4(6):a014241. doi:10.1101/cshperspect.a014241
   Google Scholar
• Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020;21(5):255–267. doi:10.1038/s41580-020-0215-2
   PubMed Web of Science ®Google Scholar
• Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–264. doi:10.1016/j.semcancer.2006.07.014
   PubMed Web of Science ®Google Scholar
• Ji H, Wu G, Zhan X, et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One. 2011;6(10):e26057. doi:10.1371/journal.pone.0026057
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–482. doi:10.1016/j.ccr.2008.05.005
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Gan L, Xiu R, Ren P, et al. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. Oncogene. 2016;35(23):3037–3048. doi:10.1038/onc.2015.360
   PubMed Web of Science ®Google Scholar
• Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012;44(1):127–139. doi:10.1007/s10863-012-9428-1
   PubMed Web of Science ®Google Scholar
• Curtis NJ, Mooney L, Hopcroft L, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget. 2017;8(41):69219–69236. doi:10.18632/oncotarget.18215
   PubMedGoogle Scholar
• Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem Int. 2016;99:110–132. doi:10.1016/j.neuint.2016.06.011
   PubMed Web of Science ®Google Scholar
• Gassull MA. Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease. Aliment Pharm Ther. 2006;24:90–95. doi:10.1111/j.1365-2036.2006.03067.x
   PubMed Web of Science ®Google Scholar
• Cuff MA, Shirazi-Beechey SP. The importance of butyrate transport to the regulation of gene expression in the colonic epithelium. Biochem Soc Trans. 2004;32(Pt 6):1100–1102. doi:10.1042/BST0321100
   PubMedGoogle Scholar
• Cuff MA, Lambert DW, Shirazi-Beechey SP. Substrate-induced regulation of the human colonic monocarboxylate transporter, MCT1. J Physiol. 2002;539(Pt 2):361–371. doi:10.1113/jphysiol.2001.014241
   PubMed Web of Science ®Google Scholar
• Borthakur A, Saksena S, Gill RK, Alrefai WA, Ramaswamy K, Dudeja PK. Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: involvement of NF-kappa B pathway. J Cell Biochem. 2008;103(5):1452–1463. doi:10.1002/jcb.21532
   PubMed Web of Science ®Google Scholar
• Borthakur A, Priyamvada S, Kumar A, et al. A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1. Am J Physiol Gastrointest Liver Physiol. 2012;303(10):G1126–G1133. doi:10.1152/ajpgi.00308.2012
   PubMed Web of Science ®Google Scholar
• Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451. doi:10.1016/j.pharmthera.2019.107451
   PubMed Web of Science ®Google Scholar
• Ge H, Weiszmann J, Reagan JD, et al. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J Lipid Res. 2008;49(4):797–803. doi:10.1194/jlr.M700513-JLR200
   PubMed Web of Science ®Google Scholar
• Kuei C, Yu J, Zhu J, et al. Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions. Mol Pharmacol. 2011;80(5):848–858. doi:10.1124/mol.111.074500
   PubMed Web of Science ®Google Scholar
• Roland CL, Arumugam T, Deng DF, et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 2014;74(18):5301–5310. doi:10.1158/0008-5472.CAN-14-0319
   PubMed Web of Science ®Google Scholar
• Lee YJ, Shin KJ, Park SA, et al. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. Oncotarget. 2016;7(43):70898–70911. doi:10.18632/oncotarget.12286
   PubMedGoogle Scholar
• Liu C, Kuei C, Zhu J, et al. 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J Pharmacol Exp Ther. 2012;341(3):794–801. doi:10.1124/jpet.112.192799
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang M, Zhang K, et al. Lactate enhanced the effect of parathyroid hormone on osteoblast differentiation via GPR81-PKC-Akt signaling. Biochem Biophys Res Commun. 2018;503(2):737–743. doi:10.1016/j.bbrc.2018.06.069
   PubMed Web of Science ®Google Scholar
• Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910–2919. doi:10.1172/JCI42273
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9(3):352–355. doi:10.1038/nm824
   PubMed Web of Science ®Google Scholar
• Alavi MS, Karimi G, Roohbakhsh A. The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: a review. Life Sci. 2019;224:33–40. doi:10.1016/j.lfs.2019.03.045
   PubMed Web of Science ®Google Scholar
• Bardhan K, Paschall AV, Yang DF, et al. IFN gamma induces DNA methylation-silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer. Cancer Immunol Res. 2015;3(7):795–805. doi:10.1158/2326-6066.CIR-14-0164
   PubMed Web of Science ®Google Scholar
• Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67. doi:10.1038/nm.1889
   PubMed Web of Science ®Google Scholar
• Radhakrishnan H, Walther W, Zincke F, et al. MACC1-The first decade of a key metastasis molecule from gene discovery to clinical translation. Cancer Metast Rev. 2018;37(4):805–820. doi:10.1007/s10555-018-9771-8
   PubMed Web of Science ®Google Scholar
• Wang C, Wen Z, Xie J, et al. MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer. Biochem Biophys Res Commun. 2017;485(3):665–671. doi:10.1016/j.bbrc.2017.02.096
   PubMed Web of Science ®Google Scholar
• Alrefai WA, Tyagi S, Gill R, et al. Regulation of butyrate uptake in Caco-2 cells by phorbol 12-myristate 13-acetate. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):G197–G203. doi:10.1152/ajpgi.00144.2003
   PubMed Web of Science ®Google Scholar
• Saksena S, Dwivedi A, Gill RK, et al. PKC-dependent stimulation of the human MCT1 promoter involves transcription factor AP2. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G275–G283. doi:10.1152/ajpgi.90503.2008
   PubMed Web of Science ®Google Scholar
• Fanjul C, Barrenetxe J, Lostao MP, Ducroc R. Modulation of intestinal L-glutamate transport by luminal leptin. J Physiol Biochem. 2015;71(2):311–317. doi:10.1007/s13105-015-0414-z
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432. doi:10.1038/372425a0
   PubMed Web of Science ®Google Scholar
• Buyse M, Sitaraman SV, Liu X, Bado A, Merlin D. Luminal leptin enhances CD147/MCT-1-mediated uptake of butyrate in the human intestinal cell line Caco2-BBE. J Biol Chem. 2002;277(31):28182–28190. doi:10.1074/jbc.M203281200
   PubMed Web of Science ®Google Scholar
• Ranasinghe A, Schwarz MA. Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension. Biochem Pharmacol. 2022;204:115245. doi:10.1016/j.bcp.2022.115245
   PubMed Web of Science ®Google Scholar
• Felmlee MA, Jones RS, Rodriguez-Cruz V, Follman KE, Morris ME. Monocarboxylate Transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. 2020;72(2):466–485. doi:10.1124/pr.119.018762
   PubMed Web of Science ®Google Scholar
• Fisel P, Kruck S, Winter S, et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin Cancer Res. 2013;19(18):5170–5181. doi:10.1158/1078-0432.CCR-13-1180
   PubMed Web of Science ®Google Scholar
• Asada K, Miyamoto K, Fukutomi T, et al. Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. Oncology. 2003;64(4):380–388. doi:10.1159/000070297
   PubMed Web of Science ®Google Scholar
• Ng HK, Pang J, Kwok K. miRNA-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. J Neuropath Exp Neur. 2009;68(5):567.
   Web of Science ®Google Scholar
• Liang D, Zhang Y, Han J, et al. Embryonic stem cell-derived pancreatic endoderm transplant with MCT1-suppressing miR-495 attenuates type II diabetes in mice. Endocr J. 2015;62(10):907–920. doi:10.1507/endocrj.EJ15-0186
   PubMed Web of Science ®Google Scholar
• Romero-Cordoba SL, Rodriguez-Cuevas S, Bautista-Pina V, et al. Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer. Sci Rep. 2018;8(1):12252.
   PubMedGoogle Scholar
• Xu WF, Zhang ZJ, Zou KJ, et al. MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. Cell Death Dis. 2017;8(5):e2761.
   PubMedGoogle Scholar
• Zhao Y, Li W, Li M, et al. Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma. Exp Cell Res. 2019;384(1):111591. doi:10.1016/j.yexcr.2019.111591
   PubMed Web of Science ®Google Scholar
• Luo EF, Wang D, Yan GL, et al. The NF-kappa B/miR-425-5p/MCT4 axis: a novel insight into diabetes-induced endothelial dysfunction. Mol Cell Endocrinol. 2020;500:110641.
   PubMed Web of Science ®Google Scholar
• Fan Q, Yang L, Zhang X, et al. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/beta-catenin signaling pathway activation in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2018;37(1):9. doi:10.1186/s13046-018-0673-y
   PubMedGoogle Scholar
• Sprowl-Tanio S, Habowski AN, Pate KT, et al. Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer Metab. 2016;4(1):20. doi:10.1186/s40170-016-0159-3
   PubMedGoogle Scholar
• Hadjiagapiou C, Borthakur A, Dahdal RY, et al. Role of USF1 and USF2 as potential repressor proteins for human intestinal monocarboxylate transporter 1 promoter. Am J Physiol Gastr L. 2005;288(6):G1118–G1126.
   PubMed Web of Science ®Google Scholar
• Diehl K, Dinges LA, Helm O, et al. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells. Oncogene. 2018;37(1):39–51. doi:10.1038/onc.2017.299
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J. 2007;21(10):2602–2612. doi:10.1096/fj.07-8174com
   PubMed Web of Science ®Google Scholar
• Becker HM, Hirnet D, Fecher-Trost C, Sultemeyer D, Deitmer JW. Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase. J Biol Chem. 2005;280(48):39882–39889. doi:10.1074/jbc.M503081200
   PubMed Web of Science ®Google Scholar
• Klier M, Andes FT, Deitmer JW, Becker HM. Intracellular and extracellular carbonic anhydrases cooperate non-enzymatically to enhance activity of monocarboxylate transporters. J Biol Chem. 2014;289(5):2765–2775. doi:10.1074/jbc.M113.537043
   PubMed Web of Science ®Google Scholar
• Mboge MY, Chen Z, Khokhar D, et al. A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells. Biochem J. 2019;476(10):1497–1513. doi:10.1042/BCJ20190177
   PubMedGoogle Scholar
• Aspatwar A, Tolvanen MEE, Schneider HP, et al. Catalytically inactive carbonic anhydrase-related proteins enhance transport of lactate by MCT1. FEBS Open Bio. 2019;9(7):1204–1211. doi:10.1002/2211-5463.12647
   PubMed Web of Science ®Google Scholar
• Choi SH, Kim MY, Yoon YS, et al. Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A. Biochim Biophys Acta Gene Regul Mech. 2019;1862(8):771–785. doi:10.1016/j.bbagrm.2019.06.004
   PubMed Web of Science ®Google Scholar
• Furugen A, Kobayashi M, Narumi K, et al. AMP-activated protein kinase regulates the expression of monocarboxylate transporter 4 in skeletal muscle. Life Sci. 2011;88(3–4):163–168. doi:10.1016/j.lfs.2010.11.003
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Narumi K, Furugen A, Iseki K. Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). Pharmacol Ther. 2021;226:107862. doi:10.1016/j.pharmthera.2021.107862
   PubMed Web of Science ®Google Scholar
• Narumi K, Kobayashi M, Otake S, et al. Regulation of human monocarboxylate transporter 4 in skeletal muscle cells: the role of protein kinase C (PKC). Int J Pharm. 2012;428(1–2):25–32. doi:10.1016/j.ijpharm.2012.02.021
   PubMedGoogle Scholar
• Wang D, Wang Q, Yan G, et al. High glucose and interleukin 1beta-induced apoptosis in human umbilical vein endothelial cells involves in down-regulation of monocarboxylate transporter 4. Biochem Biophys Res Commun. 2015;466(4):607–614. doi:10.1016/j.bbrc.2015.09.016
   PubMed Web of Science ®Google Scholar
• Tong YH, Hu XP, Xiang XP, Fang L. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer. Transl Cancer Res. 2021;10(3):1336–1345. doi:10.21037/tcr-20-3117
   PubMed Web of Science ®Google Scholar
• Eilertsen M, Andersen S, Al-Saad S, et al. Monocarboxylate transporters 1–4 in NSCLC: MCT1 is an independent prognostic marker for survival. PLoS One. 2014;9(9):e105038. doi:10.1371/journal.pone.0105038
   PubMed Web of Science ®Google Scholar
• Guan X, Morris ME. In vitro and in vivo efficacy of AZD3965 and Alpha-Cyano-4-hydroxycinnamic acid in the murine 4T1 breast tumor model. AAPS J. 2020;22(4):84. doi:10.1208/s12248-020-00466-9
   PubMed Web of Science ®Google Scholar
• Izumi H, Takahashi M, Uramoto H, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 2011;102(5):1007–1013. doi:10.1111/j.1349-7006.2011.01908.x
   PubMed Web of Science ®Google Scholar
• Noble RA, Bell N, Blair H, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102(7):1247–1257. doi:10.3324/haematol.2016.163030
   PubMed Web of Science ®Google Scholar
• Noble RA, Thomas H, Zhao Y, et al. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. Brit J Cancer. 2022;127(5):937–947. doi:10.1038/s41416-022-01848-w
   PubMed Web of Science ®Google Scholar
• Zhao B, Aggarwal A, Im SY, Viswanathan K, Landa I, Nehs MA. Effect of lactate export inhibition on anaplastic thyroid cancer growth and metabolism. J Am Coll Surg. 2022;234(6):1044–1050. doi:10.1097/XCS.0000000000000226
   PubMed Web of Science ®Google Scholar
• Plummer R, Halford S, Jones P, et al. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. Ann Oncol. 2018;29:iii9. doi:10.1093/annonc/mdy048.008
   Google Scholar
• Beloueche-Babari M, Wantuch S, Casals Galobart T, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77(21):5913–5924. doi:10.1158/0008-5472.CAN-16-2686
   PubMed Web of Science ®Google Scholar
• Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10. Biochem J. 2010;425(3):523–530. doi:10.1042/BJ20091515
   PubMedGoogle Scholar
• Draoui N, Schicke O, Seront E, et al. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol Cancer Ther. 2014;13(6):1410–1418. doi:10.1158/1535-7163.MCT-13-0653
   PubMed Web of Science ®Google Scholar
• Gurrapu S, Jonnalagadda SK, Alam MA, et al. Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: in vitro and in vivo studies as potential anticancer agents. Bioorg Med Chem Lett. 2016;26(14):3282–3286. doi:10.1016/j.bmcl.2016.05.054
   PubMed Web of Science ®Google Scholar
• Draoui N, Schicke O, Fernandes A, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorgan Med Chem. 2013;21(22):7107–7117. doi:10.1016/j.bmc.2013.09.010
   PubMed Web of Science ®Google Scholar
• Tateishi H, Tsuji AB, Kato K, et al. Synthesis and evaluation of C-11-labeled coumarin analog as an imaging probe for detecting monocarboxylate transporters expression. Bioorg Med Chem Lett. 2017;27(21):4893–4897. doi:10.1016/j.bmcl.2017.09.033
   PubMed Web of Science ®Google Scholar
• Quanz M, Bender E, Kopitz C, et al. Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol Cancer Ther. 2018;17(11):2285–2296. doi:10.1158/1535-7163.MCT-17-1253
   PubMed Web of Science ®Google Scholar
• Cluntun AA, Badolia R, Lettlova S, et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab. 2021;33(3):629–648 e610. doi:10.1016/j.cmet.2020.12.003
   PubMedGoogle Scholar
• Fang Y, Liu WR, Tang Z, et al. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology. 2022. doi:10.1002/hep.32348
   Google Scholar
• Futagi Y, Kobayashi M, Narumi K, Furugen A, Iseki K. Identification of a selective inhibitor of human monocarboxylate transporter 4. Biochem Biophys Res Commun. 2018;495(1):427–432. doi:10.1016/j.bbrc.2017.10.025
   PubMed Web of Science ®Google Scholar
• Mora E, Guglielmotti A, Biondi G, Sassone-Corsi P. Bindarit An anti-inflammatory small molecule that modulates the NF kappa B pathway. Cell Cycle. 2012;11(1):159–169. doi:10.4161/cc.11.1.18559
   PubMed Web of Science ®Google Scholar
• Colen CB, Shen YM, Ghoddoussi F, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia. 2011;13(7):620–632. doi:10.1593/neo.11134
   PubMed Web of Science ®Google Scholar
• Diers AR, Broniowska KA, Chang CF, Hogg N. Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J. 2012;444(3):561–571. doi:10.1042/BJ20120294
   PubMed Web of Science ®Google Scholar
• Hildyard JC, Halestrap AP. Identification of the mitochondrial pyruvate carrier in Saccharomyces cerevisiae. Biochem J. 2003;374(Pt 3):607–611. doi:10.1042/bj20030995
   PubMedGoogle Scholar
• Wagner W, Ciszewski WM, Kania KD. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun Signal. 2015;13(1):36. doi:10.1186/s12964-015-0114-x
   PubMedGoogle Scholar
• Hamdan L, Arrar Z, Al Muataz Y, et al. Alpha cyano-4-hydroxy-3-methoxycinnamic acid inhibits proliferation and induces apoptosis in human breast cancer cells. PLoS One. 2013;8(9):e72953. doi:10.1371/journal.pone.0072953
   PubMed Web of Science ®Google Scholar
• Jonnalagadda S, Jonnalagadda SK, Ronayne CT, et al. Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors. Oncotarget. 2019;10(24):2355–2368. doi:10.18632/oncotarget.26760
   PubMedGoogle Scholar
• Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 2018;233(1):153–161. doi:10.1002/jcp.25804
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Alany RG, Pierscionek B. Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens. J Pharm Pharmacol. 2015;67(4):537–550. doi:10.1111/jphp.12355
   PubMed Web of Science ®Google Scholar
• Nancolas B, Guo LL, Zhou R, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473(7):929–936. doi:10.1042/BJ20151120
   PubMed Web of Science ®Google Scholar
• Puri S, Stefan K, Khan SL, Pahnke J, Stefan SM, Juvale K. Indole derivatives as new structural class of potent and antiproliferative inhibitors of monocarboxylate transporter 1 (MCT1; SLC16A1). J Med Chem. 2022;66(1):657–676. doi:10.1021/acs.jmedchem.2c01612
   PubMed Web of Science ®Google Scholar
• Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD. Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem. 2014;57(17):7317–7324. doi:10.1021/jm500640x
   PubMed Web of Science ®Google Scholar
• Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ, Bar EE. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017;7(1):4292. doi:10.1038/s41598-017-04612-w
   PubMedGoogle Scholar